Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BMS-986258 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986258 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
CC-90002 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
CC-90002 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
BMS-986360 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
BMS-986360 by Bristol-Myers Squibb for Sarcomas: Likelihood of Approval
BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
Romidepsin by Bristol-Myers Squibb for Thyroid Cancer: Likelihood of Approval
Romidepsin is under clinical development by Bristol-Myers Squibb and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase...
Romidepsin by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Romidepsin is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for T-Cell Lymphomas: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...
Pomalidomide by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Pomalidomide is under clinical development by Bristol-Myers Squibb and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData,...
Sitravatinib malate by Bristol-Myers Squibb for Synovial Sarcoma: Likelihood of Approval
Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Synovial Sarcoma. According to GlobalData,...
Dasatinib by Bristol-Myers Squibb for Breast Cancer: Likelihood of Approval
Dasatinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Breast Cancer. According to GlobalData, Phase...
BMS-813160 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-813160 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's MYK-224?
MYK-224 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Diastolic Heart Failure (HFpEF)....
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Afimetoran?
Afimetoran is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Systemic Lupus Erythematosus. According...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Golcadomide?
Golcadomide is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Diffuse Large B-Cell Lymphoma....
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Farletuzumab Ecteribulin?
Farletuzumab Ecteribulin is a monoclonal antibody conjugated commercialized by Bristol-Myers Squibb, with a leading Phase II program in Endometrial Cancer....
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's BMS-986012?
BMS-986012 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Small-Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Danicamtiv?
Danicamtiv is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Systolic Heart Failure. According...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Milvexian?
Milvexian is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Atrial Flutter. According to...